Newborn Screening for Cystic Fibrosis in Iceland: a Pilot Study

Introduction: Cystic fibrosis (CF) is one of the life-shortening autosomal recessive diseases in the Caucasian populations of Europe and North America which is detected and diagnosed through newborn screening (NBS). Prior to starting a NBS program for CF, it is vital to have a fail-safe procedure to...

Full description

Bibliographic Details
Main Author: Lizette Cinco Marchadesch 1995-
Other Authors: Háskóli Íslands
Format: Master Thesis
Language:English
Published: 2023
Subjects:
Online Access:http://hdl.handle.net/1946/43369
_version_ 1821551372522225664
author Lizette Cinco Marchadesch 1995-
author2 Háskóli Íslands
author_facet Lizette Cinco Marchadesch 1995-
author_sort Lizette Cinco Marchadesch 1995-
collection Skemman (Iceland)
description Introduction: Cystic fibrosis (CF) is one of the life-shortening autosomal recessive diseases in the Caucasian populations of Europe and North America which is detected and diagnosed through newborn screening (NBS). Prior to starting a NBS program for CF, it is vital to have a fail-safe procedure to minimize risks and maximize benefits. The calculated incidence of cystic fibrosis in Iceland is 1:8,135 based on number of births and CF patients diagnosed clinically from 1955 to 2022. Aim: The objective of this pilot study aims to establish the feasibility of newborn screening for CF in Iceland that will provide a reliable screening process. Methods: Newborn screening for cystic fibrosis was performed by measuring immunoreactive trypsinogen (IRT) with an immunoassay, using the PerkinElmer DELFIA IRT kit. A total of 4,520 stored dried blood spots from the year 2020 were tested and used as a study population. The significance between IRT concentrations and study variables, birthweight, gestational age, age at sampling, length, gender, Apgar score, amino acids, acylcarnitines, and season of child’s birth was conducted with a p-value of 0.05 using IBM SPSS 27.01.1. Results: On the first screening of IRT, 62 samples were above cut-off level (>50 ng/mL). But upon reassaying from the same DBS, 58 samples remained elevated. No newborn was diagnosed with CF in 2020. The elevated IRT concentration could be most likely due to CF carriers or from demographic factors which showed statistically significant association to IRT. Through stepwise logarithmic regression analysis, factors which showed statistically significant to IRT concentration were methionine, season of sampling, C3, Apgar score, birthweight, tyrosine, C14:1, C18:1, C2, and C16:OH. Additionally, all independent variables (significant and nonsignificant) were grouped and analyzed for significance to mean ranks of IRT using Kruskal-Wallis test. The categorized variables which were statistically significant to mean ranks of IRT were the following: gestational age, ...
format Master Thesis
genre Iceland
genre_facet Iceland
id ftskemman:oai:skemman.is:1946/43369
institution Open Polar
language English
op_collection_id ftskemman
op_relation http://hdl.handle.net/1946/43369
publishDate 2023
record_format openpolar
spelling ftskemman:oai:skemman.is:1946/43369 2025-01-16T22:34:35+00:00 Newborn Screening for Cystic Fibrosis in Iceland: a Pilot Study Farkönnun á skimun nýbura fyrir slímseigjusjúkdómi Lizette Cinco Marchadesch 1995- Háskóli Íslands 2023-01 application/pdf image/jpeg http://hdl.handle.net/1946/43369 en eng http://hdl.handle.net/1946/43369 Lífeindafræði Thesis Master's 2023 ftskemman 2023-06-28T22:53:35Z Introduction: Cystic fibrosis (CF) is one of the life-shortening autosomal recessive diseases in the Caucasian populations of Europe and North America which is detected and diagnosed through newborn screening (NBS). Prior to starting a NBS program for CF, it is vital to have a fail-safe procedure to minimize risks and maximize benefits. The calculated incidence of cystic fibrosis in Iceland is 1:8,135 based on number of births and CF patients diagnosed clinically from 1955 to 2022. Aim: The objective of this pilot study aims to establish the feasibility of newborn screening for CF in Iceland that will provide a reliable screening process. Methods: Newborn screening for cystic fibrosis was performed by measuring immunoreactive trypsinogen (IRT) with an immunoassay, using the PerkinElmer DELFIA IRT kit. A total of 4,520 stored dried blood spots from the year 2020 were tested and used as a study population. The significance between IRT concentrations and study variables, birthweight, gestational age, age at sampling, length, gender, Apgar score, amino acids, acylcarnitines, and season of child’s birth was conducted with a p-value of 0.05 using IBM SPSS 27.01.1. Results: On the first screening of IRT, 62 samples were above cut-off level (>50 ng/mL). But upon reassaying from the same DBS, 58 samples remained elevated. No newborn was diagnosed with CF in 2020. The elevated IRT concentration could be most likely due to CF carriers or from demographic factors which showed statistically significant association to IRT. Through stepwise logarithmic regression analysis, factors which showed statistically significant to IRT concentration were methionine, season of sampling, C3, Apgar score, birthweight, tyrosine, C14:1, C18:1, C2, and C16:OH. Additionally, all independent variables (significant and nonsignificant) were grouped and analyzed for significance to mean ranks of IRT using Kruskal-Wallis test. The categorized variables which were statistically significant to mean ranks of IRT were the following: gestational age, ... Master Thesis Iceland Skemman (Iceland)
spellingShingle Lífeindafræði
Lizette Cinco Marchadesch 1995-
Newborn Screening for Cystic Fibrosis in Iceland: a Pilot Study
title Newborn Screening for Cystic Fibrosis in Iceland: a Pilot Study
title_full Newborn Screening for Cystic Fibrosis in Iceland: a Pilot Study
title_fullStr Newborn Screening for Cystic Fibrosis in Iceland: a Pilot Study
title_full_unstemmed Newborn Screening for Cystic Fibrosis in Iceland: a Pilot Study
title_short Newborn Screening for Cystic Fibrosis in Iceland: a Pilot Study
title_sort newborn screening for cystic fibrosis in iceland: a pilot study
topic Lífeindafræði
topic_facet Lífeindafræði
url http://hdl.handle.net/1946/43369